skip to content »

Section of Atherosclerosis

Houston, Texas

BCM faculty, staff and trainees are the heart of the organization.
Section of Atherosclerosis and Vascular Medicine
not shown on screen

Chu-Huang (Mendel) Chen, M.D.,Ph.D.

Photo Chu-Huang (Mendel) Chen, M.D., Ph.D.

Positions:

  • Associate Professor of Medicine
  • Clinical Director, Behavioral Medicine Research Center

Contact Information:

Phone: 713-798-4217
Fax: 713-798-4121
E-mail: cchen@bcm.edu

Basic Research Interests:

Dr. Chen and his associates have demonstrated that a novel atherogenic, electronegative low-density lipoprotein (LDL) subfraction can inhibit angiogenesis and induce apoptosis in vascular endothelial cells by inhibiting the transcription of fibroblast growth factor 2 (FGF2). The main goal of their research now is to identify the active lipid components of this electronegative LDL species. Using high-performance liquid chromatography and mass spectrometry, they are characterizing the discrete components of phospholipids and neutral lipids isolated exclusively from this particular LDL species. To determine the plasma membrane receptors responsible for transducing the signals of this electronegative LDL and its active components, Dr. Chen's team is testing a novel sequential receptor model that involves the platelet-activating factor and leptin-like oxidized LDL receptors. To inhibit the translation of these receptors, small interfering RNAs against each gene have been generated. In many cell types, FGF2 activates phosphatidyl 3'-kinase (PI3K), which in turn activates protein kinase Akt. Dr. Chen has demonstrated a novel FGF2-PI3K-Akt autoregulatory loop in vascular endothelial cells. To delineate the intracellular signaling pathways, Dr. Chen's team is examining the interactions between the FGF2-PI3K-Akt loop and other apoptosis regulatory systems. Several cell lines have been established to study these mechanisms. The goal is to fully characterize a novel atherogenic and proinflammatory LDL species. These studies will provide the basis for development of new therapeutic strategies aimed at the plasma, cell membrane receptors, and genes that are activated by this atherogenic lipid.

Clinical Research Interests:

Electronegative LDL and Heart
At the American College of Cardiology Scientific Sessions 2004, Dr. Chen presented work demonstrating that the aforementioned electronegative LDL species is a novel atherogenic lipoprotein independent of other risk factors and that compliance to statin treatment can effectively reduce its abundance in patients with hypercholesterolemia. The current clinical foci of their study are threefold: 1) epidemiological analysis of plasma concentrations of this electronegative LDL species in patients with obesity or metabolic syndrome, 2) determination of whether electronegative LDL plays a role in acute coronary syndromes and destabilization of vulnerable plaques, 3) determination of whether the excessive abundance of this LDL species is related to increased left ventricular mass, which is a risk factor of sudden cardiac death.

Tai Chi and Heart
Tai Chi exercise has long been considered to the beneficial to be cardiovascular system, but scientific studies at the cell level have not been reported. There are several different styles of Tai Chi, but all of them originated from the Chen style. As Medical Director of the USA Chen Tai Chi Federation, Dr. Chen and his associates will conduct studies to link the clinical benefits of Tai Chi exercise to cardiovascular disease prevention. One of the goals is to determine the effect of Tai Chi on electronegative LDL reduction and subsequent endothelial cell protection in patients with metabolic syndrome.

Selected Publications:

E-mail this page to a friend